Oppenheimer Asset Management Inc. Sells 6,377 Shares of Azenta, Inc. (NASDAQ:AZTA)

Oppenheimer Asset Management Inc. decreased its position in Azenta, Inc. (NASDAQ:AZTA - Free Report) by 35.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,861 shares of the company's stock after selling 6,377 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Azenta were worth $593,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of AZTA. Conestoga Capital Advisors LLC lifted its holdings in Azenta by 65.0% in the fourth quarter. Conestoga Capital Advisors LLC now owns 1,577,881 shares of the company's stock valued at $78,894,000 after buying an additional 621,830 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Azenta by 94.4% during the fourth quarter. Principal Financial Group Inc. now owns 221,083 shares of the company's stock valued at $11,054,000 after purchasing an additional 107,339 shares during the period. New York State Common Retirement Fund raised its holdings in shares of Azenta by 41.0% during the fourth quarter. New York State Common Retirement Fund now owns 265,983 shares of the company's stock valued at $13,299,000 after purchasing an additional 77,409 shares during the period. Royce & Associates LP raised its holdings in shares of Azenta by 7.8% during the third quarter. Royce & Associates LP now owns 739,977 shares of the company's stock valued at $35,844,000 after purchasing an additional 53,584 shares during the period. Finally, Peregrine Capital Management LLC raised its holdings in shares of Azenta by 53.6% during the fourth quarter. Peregrine Capital Management LLC now owns 149,377 shares of the company's stock valued at $7,469,000 after purchasing an additional 52,120 shares during the period. Institutional investors and hedge funds own 99.08% of the company's stock.

Remove Ads

Azenta Price Performance

Shares of NASDAQ:AZTA traded up $2.57 during midday trading on Friday, hitting $43.68. 810,259 shares of the company's stock were exchanged, compared to its average volume of 579,068. The stock has a 50 day moving average price of $49.26 and a 200-day moving average price of $47.39. The company has a market cap of $2.00 billion, a PE ratio of -14.66 and a beta of 1.52. Azenta, Inc. has a 12 month low of $38.82 and a 12 month high of $65.51.

Azenta (NASDAQ:AZTA - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.05 by $0.03. Azenta had a negative net margin of 24.91% and a positive return on equity of 1.25%. On average, analysts anticipate that Azenta, Inc. will post 0.53 EPS for the current fiscal year.

Analysts Set New Price Targets

AZTA has been the topic of several research reports. Evercore ISI upped their price objective on shares of Azenta from $50.00 to $52.00 and gave the company an "in-line" rating in a report on Thursday, February 6th. Needham & Company LLC upped their price objective on shares of Azenta from $55.00 to $59.00 and gave the company a "buy" rating in a report on Thursday, February 6th. Stephens reiterated an "overweight" rating and set a $60.00 price objective on shares of Azenta in a report on Thursday, January 2nd. Finally, TD Cowen raised shares of Azenta to a "hold" rating in a research report on Thursday, February 27th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Azenta presently has a consensus rating of "Hold" and a consensus target price of $58.75.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.